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A B S T R A C T
Widespread white matter abnormalities have been reported in schizophrenia, a disorder frequently characterised
as a dysconnection syndrome. White matter connectivity in schizophrenia has been predominantly investigated
using diﬀusion weighted imaging, with reductions in fractional anisotropy throughout the brain often inter-
preted as an indicator of abnormal myelination. However, diﬀusion weighted imaging lacks speciﬁcity and as
such a number of microstructural factors besides myelin may be contributing to these results. We utilised
multicomponent driven equilibrium single pulse observation of T1 and T2 (mcDESPOT) in medicated patients
with chronic schizophrenia, stratiﬁed by treatment response status, and healthy controls, in order to assess
myelin water fraction (MWF) in these groups. In addition, we assessed cognitive control using the Stroop task to
investigate how response inhibition relates to myelination in patients and controls. Both treatment resistant
(n=22) and treatment responsive (n=21) patients showed reduced MWF compared to healthy controls
(n=24) in bilateral fronto-occipital fasciculi, particularly evident in the vicinity of the striatum und extending
to the cerebellum, with no diﬀerence between patient groups. Patients showed greater reaction time interference
on the Stroop task compared to healthy controls, with no diﬀerence between patient groups. Stroop interference
was signiﬁcantly negatively correlated with MWF in the corpus callosum across groups, and MWF diﬀerences in
this region mediated the behavioural group eﬀects on the Stroop task. These ﬁndings support the suitability of
mcDESPOT as a myelin-speciﬁc measure of abnormal connectivity in schizophrenia, and suggest that treatment
resistant schizophrenia is not characterised by more severe abnormalities in myelination or cognitive control
compared to treatment responsive schizophrenia.
1. Introduction
Schizophrenia, a debilitating psychotic disorder, has been widely
described in terms of a dysconnection syndrome (Friston et al., 2016;
Friston and Frith, 1995; Volkow et al., 1988). Symptoms of psychosis,
including delusions and hallucinations, are in part suggested to emerge
as a result of inadequate integration of neural processes in the brain.
Both functional and structural connectivity dysfunctions have been
observed in schizophrenia (Pettersson-Yeo et al., 2011) and it is by now
widely established that white matter abnormalities are pervasive in the
disorder (Klauser et al., 2017). These have been shown to be associated
with abnormal functional activation (Marenco et al., 2012) and con-
nectivity (Liu et al., 2011) as well as symptoms (Canu et al., 2015). The
most consistent ﬁndings show white matter changes in frontal and
temporal lobes, as well as in the corpus callosum and internal capsule
(Kubicki et al., 2007; Samartzis et al., 2014; Wheeler and Voineskos,
2014).
Symptoms of psychosis are treated with antipsychotics which act via
subcortical dopamine receptor blockade. However, symptomatic non-
response to treatment remains an area of unmet clinical need, with
around 30% of patients with a diagnosis of schizophrenia showing in-
adequate response despite optimal treatment (Lindenmayer, 2000;
Mortimer et al., 2010). It is likely that this form of “treatment-resistant”
schizophrenia (TRS) diﬀers in terms of its underlying neurobiology
from treatment responsive schizophrenia (Mouchlianitis et al., 2016).
As a result, antipsychotic medication acting on the dopamine system
may not be targeting the underlying cause of psychosis in TRS patients.
It has been suggested that TRS is characterised by more severe or dis-
tinct patterns of structural dysconnectivity compared to treatment re-
sponsive schizophrenia (White et al., 2016), resulting in more severe
cognitive deﬁcits and psychotic symptoms. An association between
good treatment response and improved white matter integrity has been
previously shown (Garver et al., 2008), however it is unclear how
myelination speciﬁcally relates to cognitive performance in schizo-
phrenia as a function of treatment response.
Overall there is a large body of evidence suggesting that patients
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with schizophrenia show widespread decreases in white matter in-
tegrity, usually on the basis of diﬀusion weighted imaging (Wheeler and
Voineskos, 2014). The most commonly reported measure is fractional
anisotropy (FA), which indexes the degree of directionality of diﬀusing
water molecules. Changes in FA are attributed to changes in the mi-
crostructure of white matter tracts; however, these could in eﬀect be
indicators of numerous underlying features such as myelination, axon
diameter, ﬁbre density, axon number, or axonal membrane integrity.
Multicomponent driven equilibrium single pulse observation of T1 and
T2 (mcDESPOT) is a recently developed imaging technique which al-
lows for the derivation of a whole-brain myelin water fraction (MWF)
map with rapid acquisition times (Deoni et al., 2008). As a metric for
the fraction of water trapped between the myelin sheaths around the
neuronal axons, MWF has been shown to correlate strongly with his-
tological measures of myelin content (Laule et al., 2006; Webb et al.,
2003), and to provide higher speciﬁcity to myelin content as compared
with diﬀusion measures (Mädler et al., 2008; Vavasour et al., 2011).
Here we report the ﬁrst study utilising mcDESPOT in a sample of pa-
tients with a diagnosis of schizophrenia, stratiﬁed by treatment re-
sponse status, and a healthy control sample. In order to assess the re-
lationship between myelination, treatment response, and cognitive
function, we included a basic measure of executive control, the Stroop
task. The task was chosen as it represents a widely used measure of
executive control, which is known to be impaired in schizophrenia and
has been shown to be related to functional outcome (Green et al.,
2000). Impaired performance on the Stroop task in patients with schi-
zophrenia was conﬁrmed in a recent meta-analysis (Westerhausen
et al., 2011).
The aims of this study were 1) to test the utility of mcDESPOT in
detecting diﬀerences in myelination between patients with schizo-
phrenia and healthy controls, 2) to investigate whether diﬀerences in
myelination may account for diﬀerences in response to antipsychotic
treatment, 3) to explore whether myelin content as measured by
mcDESPOT modulates behavioural performance on a cognitive control
task and 4) if this is diﬀerentially impacted across treatment refractory
and treatment responsive patients with schizophrenia.
2. Material and methods
2.1. Participants
The study included 43 individuals with a diagnosis of schizophrenia
(according to ICD-10 criteria) and 24 healthy controls matched for age,
sex, and socioeconomic background. The patient sample included 22
patients who fulﬁlled criteria for treatment resistance (TRS), based on
at least two prior drug trials of 4–6weeks duration with no clinical
improvement, persistence of illness for longer than ﬁve years with no
period of good social or occupational functioning, and persistent psy-
chotic symptoms as deﬁned as a score of at least 4 (moderate) on at
least two positive symptom items of the Positive and Negative
Syndrome Scale (PANSS; Kay et al., 1987). The remaining 21 patients
fulﬁlled criteria for being in symptomatic remission (non-treatment
resistant; NTR), as deﬁned by a score of 3 or less on all items of the
PANSS (Conley and Kelly, 2001), and these symptoms having been
stable for at least 6 months (Andreasen et al., 2005). The two patient
groups were matched for age, sex, duration of illness, medication type
and dosage. Current clozapine use was an exclusion criterion for all
patients; this was to maintain the homogeneity of the patient sample -
fulﬁlling the standard criteria for treatment resistance - avoiding the
introduction of sub-groups of patients refractory to clozapine (super-
resistant patients). Chlorpromazine (CPZ) equivalent doses of medica-
tions were calculated using conversion tables. Exclusion criteria for all
subjects were a history of neurological illness, current major physical
illness, and drug dependency over the last six months. Exclusion criteria
for HC were a history of psychiatric illness and a ﬁrst-degree relative
currently or previously suﬀering from a psychotic illness. All subjects
had normal hearing and normal or corrected-to-normal vision. Demo-
graphic characteristics and clinical data are presented in Table 1.
Ethical approval was provided by the London Camberwell St Giles
Research and Ethics Committee. All participants provided informed
written consent and were compensated for their time and travel.
2.2. MRI acquisition and processing
Scans were acquired on a 3T GE Excite II MR scanner (GE
Healthcare, USA) with an 8-channel head coil. The mcDESPOT protocol
consisted of a spoiled gradient recalled echo (SPGR) sequence across
nine ﬂip angles α (TR= 8.0ms; TE=3.6ms; α=[2, 3, 4, 5, 6, 7, 9,
13, 18]°; matrix= 128×128), and a balanced steady-state free pro-
cession (bSSFP) sequence across eight ﬂip angles, acquired at radio-
frequency phase cycling patterns of 0° and 180° to correct for oﬀ-re-
sonance eﬀects (TR=3.8ms; TE=1.9ms; α=[12, 16, 21, 27, 33, 40,
51, 68]; matrix= 128×128). In addition an inversion recovery SPGR
was acquired for estimating the ﬂip angle error caused by transmitting
B1 ﬁeld inhomogeneity (TR=8.0ms; TE=3.6ms; α=5°; ma-
trix= 220×110). The ﬁeld of view was 220×220 cm and the voxel
size was 1.7mm isotropic. The full mcDESPOT sequence lasted ap-
proximately 13min.
All raw images were visually inspected for motion artefacts.
Participants with missing scans or excessive motion were re-scanned
either immediately or at their earliest convenience, resulting in a
complete dataset. Each subject's scans were linearly coregistered, and
non-brain parenchyma signal removed using BET (FMRIB Software
Library, www.fmrib.ox.ac.uk/fsl). mcDESPOT maps were processed
using our previously described open-source software (Wood et al.,
2016). Brieﬂy, ﬁrst T1 & B1 maps were calculated from the data (Deoni,
2007), then T2 & oﬀ-resonance maps (Deoni, 2009), and then ﬁnally
Myelin Water Fraction maps using a three component model and
Gaussian Region Contraction (Deoni et al., 2013). MWF maps were non-
linearly registered to the MNI152 2mm isotropic standard brain, and
smoothed using a Gaussian kernel at 5mm FWHM.
2.3. Statistical analysis
2.3.1. Whole-brain group comparisons
Whole-brain normalised MWF maps were subjected to non-para-
metric permutation tests using FSL's randomise (with 10,000 permu-
tations), and signiﬁcance values were corrected for multiple compar-
isons using threshold-free cluster enhancement (TFCE). Clusters were
deﬁned with an extent threshold of 50 voxels. We tested the eﬀect of
group (HC vs. NTR vs. TRS), adjusting for eﬀects of age and sex.
2.3.2. White matter histogram analysis
In order to analyse the distribution of WMF values within the white
matter speciﬁcally, we overlaid MWF maps with a white matter mask
obtained from the Johns Hopkins University White Matter Atlas.
Histogram analyses of white matter MWF were conducted by summing
Table 1
Means and standard deviations of histogram data per group.
HC NTR TRS
M SD M SD M SD χ2(2) P
Mean 24.19 0.98 23.33 1.30 23.31 1.24 7.61 0.022
Variance 24.02 4.57 28.93 4.71 27.90 5.00 13.49 0.001
Mode (peak
position)
27.46 1.18 27.15 1.39 26.89 1.33 2.23 > 0.05
Mode frequency
(peak height)
0.17 0.04 0.14 0.03 0.14 0.03 6.98 0.031
HC: healthy controls. NTR: non-treatment resistant schizophrenia. TRS: treatment re-
sistant schizophrenia. χ2: Kruskall-Wallis Chi squared test statistic.
L.D. Vanes et al. NeuroImage: Clinical 18 (2018) 186–191
187
the number of voxels for 100 uniform bins between 0% and 30%. Each
individual's histogram was normalised with respect to the area of the
histogram. For each subject, the mean (ﬁrst moment), variance (second
moment), peak position (mode), and peak height (frequency of voxels
in the modal bin) of the histogram were calculated and subsequently
compared between groups using non-parametric Kruskal Wallis tests.
2.4. MWF and the Stroop eﬀect
2.4.1. Stroop task
Subjects performed a standard verbal Stroop task inside the MRI
scanner. The task consisted of naming the font colour of colour words
that were either congruent (e.g. the word “yellow” printed in yellow) or
incongruent (e.g. the word ‘yellow’ printed in blue). Thirty-three con-
gruent, 33 incongruent, and 34 ﬁxation trials were presented in ran-
domised order, each with a duration of 700ms and inter-stimulus-in-
terval of 2300ms. This preceded the mcDESPOT scanning protocol.
Each subject's Stroop eﬀect was deﬁned as the diﬀerence between
their mean reaction time (RT) on incongruent trials and their mean RT
on congruent trials. The Stroop eﬀect was compared between groups
using one-way ANOVA.
We tested for correlations between whole-brain MWF and the RT
Stroop eﬀect across all subjects using randomise. For the resulting
signiﬁcant cluster, we extracted each subject's mean MWF and com-
pared these between groups. We then conducted a mediation analysis to
test whether MWF in this region mediated group diﬀerences in the RT
Stroop eﬀect. We used a bootstrap approach proposed by Preacher and
Hayes (2004) in order to test for signiﬁcance of the indirect eﬀect of
group on RT Stroop eﬀect.
3. Results
3.1. mcDESPOT group eﬀects
At whole-brain level, controlling for sex and age, there was a sig-
niﬁcant eﬀect of group in four clusters (Fig. 1): two large clusters
covering much of the right (MNI: x= 44, y=−68, z=−36,
p=0.016) and left (MNI: x=−32, y=−18, z=−2, p=0.010)
subcortical white matter including the inferior fronto-occipital fasciculi,
particularly in the vicinity of the striatum and extending to the cere-
bellum, one cluster containing the left putamen (MNI: x=−26, y= 6,
z=−6, p=0.035), and a small cluster in the right subcallosal cortex
(MNI: x= 8, y=18, z=−24, p=0.026). In each of these clusters,
post-hoc t-tests revealed that both NTR and TRS patients showed re-
ductions compared to HC, all ps < 0.05, with no diﬀerence detected
between the two patient groups, all ps > 0.05. Mean MWF within these
clusters ranged from 6% to 19% - lower than the expected range for
white matter - indicating that group diﬀerences may extend to grey
matter regions.
3.2. White matter histogram analysis
Group histograms (depicted in Fig. 2) show that voxel count peaks
in the expected range for white matter (25–30%), consistent with pre-
vious mcDESPOT reports. Both patient groups show shifts slightly
downwards and to the left, suggesting that less voxels within the white
matter fall into the normal region of MWF values.
Post-hoc Mann-Whitney tests (Bonferroni corrected for multiple
comparisons) showed that histogram means were signiﬁcantly lower in
TRS compared to HC (W=374, p=0.045), and marginally lower in
NTR compared to HC (W=353, p=0.064). The variance was greater
in both NTR and TRS compared to HC, all ps < 0.05. Peak height was
reduced in both patient groups compared to HC, although these tests
did not survive corrections for multiple comparisons. There were no
diﬀerences between NTR and TRS groups on any of the histogram
measures (Table 1).
3.3. MWF and the Stroop eﬀect
Stroop data from one HC and one TRS subject were not available
due to technical issues. There was a main eﬀect of group on RT Stroop
eﬀect. Pairwise comparisons revealed that both TRS (M=186.66ms;
SD=128.26ms) and NTR (M=169.78ms; SD=129.95ms) showed a
greater Stroop eﬀect than HC (M=85.14ms; SD=71.87), all ps <
0.05 (Bonferroni corrected), with no diﬀerence between the two pa-
tient groups, p=0.627.
A large cluster consisting of the corpus callosum (genu, body, and
splenium) was negatively related with RT Stroop eﬀect across all sub-
jects, such that higher MWF values were associated with a smaller
Stroop eﬀect (Fig. 3). We extracted mean MWF from within this cluster
for each subject for further analyses. The negative correlation was
Fig. 1. Main eﬀect of group on myelin water fraction.
Fig. 2. Normalised histograms of white matter myelin water fraction by group.
Fig. 3. Signiﬁcant correlation between Stroop eﬀect and myelin water fraction.
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evident within each group separately (HC: R=−0.35, p=0.09; NTR:
R=−0.50, p=0.021; TRS: R=−0.59, p=0.005). Pairwise com-
parisons of mean MWF in the corpus callosum between HC and the two
patient subgroups did not survive Bonferroni corrections for multiple
comparisons; hence NTR and TRS patients were pooled into a single
schizophrenia (SZ) group for the mediation analysis. We tested whether
corpus callosum MWF mediated group diﬀerences in the Stroop eﬀect
following the Baron and Kenny approach (Baron and Kenny, 1986;
Fig. 4) (Baron and Kenny, 1986). Regressing the Stroop eﬀect on group
(HC vs. SZ) showed a signiﬁcant eﬀect of group (beta= 93.08,
sd= 28.93, p=0.002). Regressing corpus callosum MWF on group
showed a signiﬁcant eﬀect of group, (beta=−0.01, sd= 0.01,
p=0.019), with higher MWF in HC (M=0.20, SD=0.1) compared to
SZ (M=0.19, SD=0.17). Finally, regressing the Stroop eﬀect on both
group and corpus callosum MWF revealed a signiﬁcant eﬀect of MWF
(beta=−3534.33, sd=765.24, p < 0.001). The eﬀect of group
(beta= 60.42, sd= 26.13, p=0.02), though signiﬁcant, was reduced
compared to the simple model regressing the Stroop eﬀect on group
alone. An analysis of the indirect eﬀect (deﬁned as the product between
the eﬀect of group on MWF and the eﬀect of MWF on RT Stroop,
controlling for group) was performed with non-parametric boot-
strapping of the sampling distribution using 5000 bootstrap samples
(Preacher and Hayes, 2004). This revealed a signiﬁcant indirect eﬀect
(95% conﬁdence interval [4.69, 67.50]); suggesting that there was a
partial mediation of the eﬀect of group on Stroop eﬀect by corpus
callosum MWF.
3.4. Relationship with clinical variables
For each of the four signiﬁcant clusters from the whole-brain MWF
group analysis as well as the corpus callosum cluster from the Stroop
analysis, we performed an exploratory analysis of correlations of MWF
with PANSS positive symptom score, PANSS negative symptom score,
illness duration, and CPZ equivalent medication dosages, both across all
patients as well as within the two patient groups separately. No cor-
relation was signiﬁcant, all ps > 0.05 (uncorrected for multiple com-
parisons).
4. Discussion
In this study we report the application of mcDESPOT (Deoni et al.,
2008) to a sample of patients with a diagnosis of schizophrenia,
stratiﬁed by treatment response, and healthy controls. We show that
this method is sensitive to reductions in myelin water fraction (MWF) in
schizophrenia compared to healthy controls, with the greatest eﬀect
evident in areas surrounding bilateral striatum, particularly the inferior
fronto-occipital fasciculus, as well as the cerebellum. Reductions in the
patient groups were bilateral but with larger clusters observed within
the left cerebral hemisphere. Mean MWF in the signiﬁcant areas were
below the expected range for white matter, thus suggesting that the
reductions included both white and grey matter voxels. Histograms of
MWF restricted to the white matter tracts allowed us to more closely
compare the distribution of values speciﬁcally in the white matter be-
tween the three groups, conﬁrming that patients' histograms were
shifted towards lower MWF values, with a greater variance compared to
healthy controls. MWF did not, however, distinguish between the two
patient subgroups, consisting of treatment resistant (TRS) and treat-
ment responsive (NTR) schizophrenia patients. This suggests that un-
derlying abnormal myelination is not a driving force behind anti-
psychotic treatment resistance at the chronic stage of the illness.
We used a standard Stroop task as a measure of executive control
and found a correlation with corpus callosum MWF, whereby greater
MWF values were associated with a smaller reaction time interference
eﬀect. This association was observable both across all subjects and
within all groups separately. A mediation analysis showed that MWF in
the corpus callosum partially mediated the group diﬀerence on the
Stroop task, such that lower MWF in patients accounted in part for the
greater interference eﬀects seen in this sample compared to controls.
The ﬁndings of reduced MWF in patients with schizophrenia com-
pared to healthy controls are in line with a large body of evidence
suggesting impaired white matter integrity in the illness (Fitzsimmons
et al., 2013; Kubicki et al., 2005; Pettersson-Yeo et al., 2011). The
proliferation of diﬀusion weighted imaging reports in recent years has
shed enormous light on disturbances of white matter in psychosis and
schizophrenia on a whole-brain basis, yet a remaining disadvantage of
the technique is the large number of microstructural factors which
could contribute to the signal. Multicomponent relaxation imaging al-
lows for a more myelin-speciﬁc quantiﬁcation of the dysfunction in
vivo. The mcDESPOT protocol is such a technique which has recently
been validated pre-clinically (Wood et al., 2016), and to our knowledge
this is the ﬁrst report to use this technique in chronic patients with a
diagnosis of schizophrenia, with an additional stratiﬁcation by treat-
ment response status. The mechanisms underlying resistance to anti-
psychotic medication are as yet not well understood (Mouchlianitis
Fig. 4. Mediation diagram of the association between group,
Stroop eﬀect, and callosal myelin water fraction.
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et al., 2016), but the lack of response despite adequate dopamine D2
receptor occupancy in TRS (Coppens et al., 1991; Wolkin et al., 1989)
suggests that striatal hyperdopaminergia may not be the principal ae-
tiology of psychotic symptoms in this patient subgroup. One study in-
vestigating white matter microstructure found reduced fractional ani-
sotropy and increased radial diﬀusivity in the corpus callosum in
chronic treatment resistant patients as compared to healthy controls
(Holleran et al., 2014); however this study did not include a remitted
patient group and as such the speciﬁcity of the ﬁnding to TRS is un-
clear. On a functional connectivity level, a recent report by White et al.
(2016) suggested that divergent pathophysiologies of striatal resting-
state connectivity are present in treatment resistant and treatment re-
sponsive schizophrenia. In addition, Sarpal and colleagues demon-
strated that functional striatal resting-state connectivity may be pre-
dictive of treatment response in ﬁrst-episode psychosis patients (Sarpal
et al., 2015). Our data suggest that these ﬁndings of functional con-
nectivity diﬀerences are not mirrored by myelin water fraction diﬀer-
ences. In this chronic patient sample, the eﬀects of illness chronicity
and exposure to medication can by deﬁnition not be entirely disen-
tangled from the eﬀects of interest and therefore remain as potential
confounds. However, the absence of group diﬀerence on these variables
as well as the lack of association with myelin water fraction suggest that
it is unlikely that these eﬀects are masking true diﬀerences in myeli-
nation between treatment resistant and responsive patients. Never-
theless, future research could usefully examine these issues by applying
the technique to patients at an earlier stage of the illness.
Cognitive deﬁcits are considered a core feature of TRS (Buckley and
Shendarkar, 2005), and as such we aimed to investigate whether a lack
of cognitive control speciﬁcally was associated with treatment re-
sistance. The presence of cognitive control deﬁcits, accompanied by
abnormal activation of networks underlying cognitive control, has been
widely established in schizophrenia (Edwards et al., 2010; Fornito
et al., 2011) and the extent of the dysfunction has been linked to
symptom severity (Woodward et al., 2003). An exacerbated inability to
exert cognitive control may thus result in the persistence of symptoms
even if a subcortical dopamine dysfunction is normalised. Cognitive
control further relies on intact connectivity of the underlying neural
network (Cole et al., 2012; Hwang et al., 2010); hence we aimed to
assess how both cognitive and structural mechanisms relate to treat-
ment response. We did not observe diﬀerences in reaction time inter-
ference on the Stroop task between the two patient groups. Thus on a
behavioural level, treatment resistance does not seem to be associated
with exacerbated cognitive control deﬁcits at the chronic stage of the
illness. However, callosal myelin reductions in schizophrenia patients
partially mediated performance diﬀerences compared to healthy in-
dividuals. Impaired white matter integrity in the corpus callosum re-
ductions have been widely observed in the illness, but this is the ﬁrst
report of a direct link between a measure of callosal myelination and
cognitive control function in schizophrenia.
This study was performed in a relatively small sample. Due to the
risk of eﬀect size overestimation associated with small sample sizes, the
results warrant replication in future multi-centre studies with larger
samples. However, recruitment and neuroimaging assessment in clin-
ical populations can be particularly challenging and typically require a
large amount of resources, and as such preliminary assessments in
smaller samples can be useful. Suckling et al. (2014) recently demon-
strated that eﬀect sizes achieved with the DESPOT sequence in a cali-
bration study on six participants was highly predictive of eﬀect sizes
observed in a large-scale multi-centre imaging study. Thus, while ac-
knowledging the need to further validate mcDESPOT imaging as a
sensitive method for studying schizophrenia, our results may be useful
for supporting the design and execution of future studies.
In summary, the current study demonstrates that mcDESPOT is a
suitable method to detect myelin alterations in schizophrenia, clarifying
the nature of the changes reported in earlier DTI studies, and this may
be a relevant marker in terms of cognitive control performance in
patients. However, we did not ﬁnd more severe myelin abnormalities in
treatment resistant patients compared to treatment responsive patients,
suggesting that primary diﬀerences in treatment response and func-
tional dysconnectivity are not driven by alterations in myelination.
Further research could usefully address potential confounds of medi-
cation exposure and illness duration by studying these measures in a
longitudinal setup in ﬁrst-episode psychosis.
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